Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus

• Published in: Gene therapy Vol. 26; no. 6; pp. 250 - 263
• Main Authors: Andrzejewski, Slawomir, Murali, Aparna, Ramlogan-Steel, Charmaine, Edwards, Katie P., Efron, Nathan, Steel, Jason C., Layton, Christopher J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2019; Nature Publishing Group
• Subjects: 13/1; 13/106; 38; 42/44; 631/250/2161; 631/250/2499; 631/326/596; Adolescent; Adult; Aged; Animals; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Biomedical and Life Sciences; Biomedicine; Care and treatment; Cell Biology; Chlorocebus aethiops; COS Cells; Dependovirus - immunology; Diabetes; Diabetes mellitus; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - immunology; Diabetics; Endocrine disorders; Female; Gene Expression; Gene Therapy; Gene Transfer Techniques - adverse effects; Genetic aspects; Health aspects; Human Genetics; Humans; Male; Middle Aged; Nanotechnology; Risk factors; Viral antibodies; Virus diseases

Recombinant Adeno-associated viruses (AAVs) are an attractive vector for gene therapy delivery which may be blocked by AAV neutralising antibodies (NAbs). As Type 1 Diabetes (T1DM) is an endocrine disease of immunological origin, it is likely that NAb profiles are altered in the disease. In this stu...